prikaz prve stranice dokumenta New-Onset Ocular Myasthenia Gravis After Booster Dose of COVID-19 Vaccine
  Download
PDF 381.92 KB
Scientific paper - Case study
New-Onset Ocular Myasthenia Gravis After Booster Dose of COVID-19 Vaccine
Cureus, 14 (2022), 7; e27213. https://doi.org/10.7759/cureus.27213
Abičić, Ana; Sitaš, Barbara; Adamec, Ivan; Bilić, Ervina; Habek, Mario

Cite this document

Abičić, A., Sitaš, B., Adamec, I., Bilić, E. & Habek, M. (2022). New-Onset Ocular Myasthenia Gravis After Booster Dose of COVID-19 Vaccine. Cureus, 14. (7). doi: 10.7759/cureus.27213

Abičić, Ana, et al. "New-Onset Ocular Myasthenia Gravis After Booster Dose of COVID-19 Vaccine." Cureus, vol. 14, no. 7, 2022. https://doi.org/10.7759/cureus.27213

Abičić, Ana, Barbara Sitaš, Ivan Adamec, Ervina Bilić and Mario Habek. "New-Onset Ocular Myasthenia Gravis After Booster Dose of COVID-19 Vaccine." Cureus 14, no. 7 (2022). https://doi.org/10.7759/cureus.27213

Abičić, A., et al. (2022) 'New-Onset Ocular Myasthenia Gravis After Booster Dose of COVID-19 Vaccine', Cureus, 14(7). doi: 10.7759/cureus.27213

Abičić A, Sitaš B, Adamec I, Bilić E, Habek M. New-Onset Ocular Myasthenia Gravis After Booster Dose of COVID-19 Vaccine. Cureus [Internet]. 2022 July 24 [cited 2024 November 07];14(7). doi: 10.7759/cureus.27213

A. Abičić, B. Sitaš, I. Adamec, E. Bilić and M. Habek, "New-Onset Ocular Myasthenia Gravis After Booster Dose of COVID-19 Vaccine", Cureus, vol. 14, no. 7, July 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:884277. [Accessed: 07 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)New-Onset Ocular Myasthenia Gravis After Booster Dose of COVID-19 Vaccine
AuthorAna Abičić
AuthorBarbara Sitaš
AuthorIvan Adamec
AuthorErvina Bilić
AuthorMario Habek
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Neurology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Neurology
Abstract (english)
Coronavirus disease 2019 (COVID-19) vaccines have been reported as possible triggers of the production of antibodies pathogenic to the peripheral nerve and neuromuscular junction. We report on a patient who experienced vertical diplopia three weeks after the booster dose of the Pfizer-BioNTech vaccine (Comirnaty®). The diagnosis of myasthenia gravis (MG) was established based on highly positive antibodies to the nicotinic acetylcholine receptor (nAChR). Treatment with pyridostigmine and prednisone was started with gradually raising doses. On a follow-up exam two months after treatment initiation, clinical improvement was noted with an almost normal bulbomotor examination. The occurrence of diplopia following COVID-19 vaccination should raise suspicion of new-onset ocular MG and testing for anti-nAChR antibodies is advised.
Keywords (english)
Languageenglish
Publication typeScientific paper - Case study
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleCureus
Numberingvol. 14, no. 7, e27213
p-ISSN2168-8184
DOIhttps://doi.org/10.7759/cureus.27213
URN:NBNurn:nbn:hr:105:884277
Publication2022-07-24
Document URLhttps://www.cureus.com/articles/105239-new-onset-ocular-myasthenia-gravis-after-booster-dose-of-covid-19-vaccine
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2023-03-21 08:37:39